GeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company's platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. The Company's development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg and Lassa Fever), as well as for use in cancer immunotherapy. The Company's clinically advanced vaccine development program is a (deoxyribonucleic acid (DNA)/MVA) vaccine regimen designed to protect against the clade B subtype of the HIV virus. The Company is developing a Tetravalent Vaccine (TV) utilizing its MVA-VLP platform to address the unmet need for a product that can respond to future filovirus epidemics.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:GOVX
- CUSIP: N/A
- Web: www.geovax.com
- Market Cap: $2.26 million
- Outstanding Shares: 58,719,000
- 50 Day Moving Avg: $0.05
- 200 Day Moving Avg: $0.06
- 52 Week Range: $0.04 - $0.11
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 0.04
- P/E Growth: 0.0000
- Annual Revenue: $1.08 million
- Price / Sales: 2.09
- Book Value: ($0.02) per share
- Price / Book: -1.75
- EBIDTA: ($2,500,000.00)
- Net Margins: -371.99%
- Return on Assets: -388.20%
- Current Ratio: 2.40%
- Quick Ratio: 2.40%
- Average Volume: 249,708 shs.
- Beta: 0.17
Frequently Asked Questions for Geovax Labs (OTCMKTS:GOVX)
What is Geovax Labs' stock symbol?
Geovax Labs trades on the OTCMKTS under the ticker symbol "GOVX."
How were Geovax Labs' earnings last quarter?
Geovax Labs Inc (OTCMKTS:GOVX) released its earnings results on Wednesday, November, 19th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. View Geovax Labs' Earnings History.
Who are some of Geovax Labs' key competitors?
Some companies that are related to Geovax Labs include Neurometrix (NURO), InspireMD (NSPR), Rosetta Genomics (ROSG), Prana Biotechnology Limited (PRAN), Delcath Systems (DCTH), Affymax (AFFY), Dextera Surgical (DXTR), Adeptus Health (ADPT), Aegerion Pharmaceuticals (AEGR), Air Methods Corp (AIRM), Alphatec Holdings (ATEC), Ariad Pharmaceuticals (ARIA), Caladrius Biosciences (CLBS), Celator Pharmaceuticals (CPXX), Cepheid (CPHD), CoLucid Pharmaceuticals (CLCD), CRH Medical Corp (CRHM) and Cynapsus Therapeutics (CYNA).
How do I buy Geovax Labs stock?
Shares of Geovax Labs can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Geovax Labs stock cost?
One share of Geovax Labs stock can currently be purchased for approximately $0.04.
Consensus Ratings for Geovax Labs (OTCMKTS:GOVX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Geovax Labs (OTCMKTS:GOVX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Geovax Labs (OTCMKTS:GOVX)Earnings History by Quarter for Geovax Labs (OTCMKTS:GOVX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Geovax Labs (OTCMKTS:GOVX)
Current Year EPS Consensus Estimate: $-0.1200 EPS
Next Year EPS Consensus Estimate: $1.0600 EPS
Dividend History for Geovax Labs (OTCMKTS:GOVX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Geovax Labs (OTCMKTS:GOVX)
Insider Ownership Percentage: 7.60%Insider Trades by Quarter for Geovax Labs (OTCMKTS:GOVX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/5/2015||Randal D Chase||Director||Buy||10,000||$0.19||$1,900.00|| |
|4/23/2015||Mark Reynolds||CFO||Buy||30,000||$0.17||$5,100.00|| |
|4/20/2015||Randal D Chase||Director||Buy||30,000||$0.17||$5,100.00|| |
Headline Trends for Geovax Labs (OTCMKTS:GOVX)
Latest Headlines for Geovax Labs (OTCMKTS:GOVX)
Geovax Labs (GOVX) Chart for Wednesday, May, 24, 2017